This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Medidata Solutions VP Of Implementation Services Honored Among PharmaVOICE 100 Most Inspiring People

Stocks in this article: MDSO

Medidata Solutions (NASDAQ: MDSO), a leading global provider of cloud-based clinical development solutions, today announced that vice president of implementation services Marco van Doeveren was named by PharmaVOICE magazine as one of the 100 most inspiring people in the life sciences industry.

The award recognizes Marco as a driving force behind Medidata’s success in addressing the unique challenges of mid-size and emerging companies in reaching the full benefits that advanced technology can bring to streamlining clinical trials.

Mid-market organizations – including pharmaceutical, biotech, medical device, academic, nonprofit and government – are looking to reap the same benefits as the large biopharma companies from Medidata’s cloud-based platform of innovative solutions. Implementations at mid-market companies frequently involve individual tailoring to account for fewer resources and accelerated timelines, and many smaller companies question whether they can get an industry-leading solution for a price they can afford.

Under Marco’s leadership, Medidata’s mid-market services team continually works to make optimal use of the Medidata platform by focusing on end-to-end processes. Using his sponsor-focused perspective to adapt Medidata’s implementation process for the mid-market, Marco’s group reliably streamlines trial processes and implements tailored solutions to each individual group without compromising efficiency or quality. As a result, his team has doubled revenue, tripled the number of projects and quadrupled the number of clients in a four-year span.

  • “Because the technology infrastructure Marco manages is leveraged by hundreds of life science companies, thousands of clinical trial professionals, and tens of thousands more investigators, nurses and patients, Marco is, very literally, one of the most influential people in clinical technology around the world,” said Glen de Vries, president, Medidata Solutions. “His passion for the industry and his detail-oriented, practical approach to working with clinical infrastructure make him a constant inspiration to his colleagues, partners and customers.”

Established eight years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life sciences industry. Nominated by thousands of PharmaVOICE readers, the PharmaVOICE 100 are selected based on well-crafted and comprehensive essays describing how individuals inspired or motivated their colleagues or peers or affected positive changes in their organizations, as well as other factors, such as community and philanthropic activities. The PharmaVOICE 100 represent a broad cross section of industry sectors, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, patient recruitment, advertising, technology and many others.

  • “Considered to be one of the most influential people in clinical technology around the world, Marco van Doeveren manages an infrastructure that is leveraged by the life sciences industry as a whole," said Taren Grom, editor and cofounder, PharmaVOICE. "In addition to his broad and extensive expertise, Mr. van Doeveren is dedicated to his teams and clients, a combination that places him squarely on the 2012 PharmaVOICE 100 list of honorees."

Connect with Medidata:

About PharmaVOICE

PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of executives who are shaping the direction of the dynamic life sciences industry. PharmaVOICE reaches more than 29,000 subscribers every month in print and more than 100,000 readers through its online version, which contains original exclusive bonus content. PharmaVOICE’s unique horizontal editorial approach cuts industry silos, providing a holistic overview of the life sciences industry, addressing a range of topics from molecule through market. By engaging compelling personalities from diverse industry sectors, PharmaVOICE provides multiple perspectives on business challenges, trends, and topics. Editorial content sparks dialog, initiates debate, and opens the lines of communication to facilitate and improve business-to-business relationships. PharmaVOICE's multiple-perspective and in-depth original forums, feature articles, topics, and departments are audience-driven. PharmaVOICE provides executives with useful peer-to-peer insights on a broad range of life sciences business practices and topics.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs